Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
8.66
+0.22 (2.61%)
Jul 12, 2024, 1:36 PM EDT - Market open

Iovance Biotherapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year
Current20232022202120202019 2018 - 2010
Market Capitalization
2,4082,0811,0092,9956,8063,493
Upgrade
Market Cap Growth
202.12%106.29%-66.33%-55.99%94.85%220.45%
Upgrade
Enterprise Value
2,1621,8106162,5566,2233,192
Upgrade
PE Ratio
--4.69-2.55-8.75-26.22-17.68
Upgrade
PS Ratio
1281.591749.89----
Upgrade
PB Ratio
3.593.562.024.8210.3711.68
Upgrade
P/FCF Ratio
-10.22-5.42-3.22-11.28-27.02-21.07
Upgrade
P/OCF Ratio
-10.77-5.75-3.45-13.14-33.18-21.98
Upgrade
EV/Sales Ratio
1135.451522.44----
Upgrade
EV/EBITDA Ratio
-9.25-4.37-1.64-7.79-24.81-16.85
Upgrade
EV/EBIT Ratio
-8.49-4.04-1.56-7.47-23.97-16.16
Upgrade
EV/FCF Ratio
-9.53-4.71-1.97-9.63-24.70-19.25
Upgrade
Debt / Equity Ratio
0.120.130.170.120.080.04
Upgrade
Debt / EBITDA Ratio
-0.20-0.18-0.23-0.22-0.21-0.06
Upgrade
Debt / FCF Ratio
-0.21-0.20-0.27-0.27-0.21-0.07
Upgrade
Quick Ratio
4.363.145.235.7211.578.00
Upgrade
Current Ratio
4.632.795.245.7011.598.10
Upgrade
Asset Turnover
0.000.000000
Upgrade
Return on Equity (ROE)
-71.50%-70.90%-82.60%-50.50%-43.80%-53.20%
Upgrade
Return on Assets (ROA)
-55.20%-55.30%-62.80%-42.70%-39.10%-48.20%
Upgrade
Return on Capital (ROIC)
-61.15%-69.73%-68.17%-49.44%-36.99%-66.63%
Upgrade
Earnings Yield
-18.43%-21.34%-39.25%-11.43%-3.81%-5.66%
Upgrade
FCF Yield
-16.60%-18.46%-31.05%-8.86%-3.70%-4.75%
Upgrade
Buyback Yield / Dilution
-24.58%-47.64%-3.82%-10.92%-11.23%-27.82%
Upgrade
Total Shareholder Return
-24.58%-47.64%-3.82%-10.92%-11.23%-27.82%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).